It is a service platform for “druggability research of innovative drugs” jointly built by Nanjing Changao Pharmaceutical Science and Technology Co., Limited with the cooperation of the university and enterprises against other competitors to seize the high ground, one of the key science and technology innovation platforms in Jiangsu, located in National Nanjing Economic Technology Development Zone, covering a total area of 10,000 m2. The service center has more than 40 senior specialists in multiple disciplines and fields, such as drug analysis, drug synthesis, drug preparation, clinical research, pharmacology and pharmacogenesis, including 1 with a doctorate degree, 19 with a master’s degree and 22 with a bachelor’s degree, forming a highly competitive scientific research team.

The service platform mainly focuses on tumor, metabolic diseases, neurodegenerative diseases, cardiovascular diseases and other harmful diseases, and carries out systematic target research and drug activity discovery research, which improves the efficiency of drug effectiveness evaluation and enriches the information content of drug activity discovery, while significantly reducing the comprehensive cost of drug development. We have been active to introduce foreign advanced science and technology and management experience, which in combination with the advantages of China’s drug development helps create a new path of new drug development in China through the innovation and reinvention of science and technology. This platform covers all procedures of new drug development, including early drug discovery, preclinical drug evaluation, preclinical research, clinical positioning and clinical research organization and monitoring, providing services related to innovative drug development research for small and medium-sized enterprises, research institutes and universities in our province and even in China, and helping them to integrate resources and promote the development and industrialization process of innovative drugs.

The technical services provided by the platform help us to realize the docking of drug research and industrialization, reduce the risk of clinical and marketing, conduct all-round evaluation and systematic research from dimensions such as drug discovery, efficacy, metabolism and toxicity risk, reduce the risk of new drug development, and improve the drug success and the utilization of resources of the whole R&D system. The platform has carried out 6 compounds in all stages of drug discovery, 7 external service projects, and obtained more than 10 million yuan in technical service income; 4 projects have been supported by the special fund for national “major new drug creation” so far.